- Published at
- by seekingalpha.com
mixed
mixed
Litigation, Debt, And Decline - Yet Bayer Seems Like A Buy (OTCMKTS:BAYZF)
Bayer's 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly. Read why BAYZF stock is a Buy.